| Unique ID issued by UMIN | UMIN000055919 |
|---|---|
| Receipt number | R000063899 |
| Scientific Title | A Prospective Observational Study Evaluating Lung Drug Clearance Using Isosorbide Dinitrate as a Probe. |
| Date of disclosure of the study information | 2024/10/23 |
| Last modified on | 2024/12/21 10:25:43 |
A Prospective Observational Study Evaluating Lung Drug Clearance Using Isosorbide Dinitrate as a Probe.
A Prospective Observational Study Evaluating Lung Drug Clearance Using Isosorbide Dinitrate as a Probe.
A Prospective Observational Study Evaluating Lung Drug Clearance Using Isosorbide Dinitrate as a Probe.
A Prospective Observational Study Evaluating Lung Drug Clearance Using Isosorbide Dinitrate as a Probe.
| Japan |
Patients scheduled for both heart catheterization and endomyocardial biopsy, with planned use of isosorbide dinitrate (ISDN) During the Procedure.
| Medicine in general | Cardiology |
Others
NO
To investigate whether isosorbide dinitrate is cleared in the lungs.
PK,PD
Insantaneous Extraction Ratio (ER) of Isosorbide Dinitrate in the lung.
Observational
| 18 | years-old | <= |
| 85 | years-old | >= |
Male and Female
Patients scheduled for both heart catheterization and endomyocardial biopsy
Patients planned to have a sheath placed in the radial artery
Patients expected to receive 1.0 mg or more of isosorbide dinitrate injection (5 mg/10 mL) during coronary angiography.
Individuals aged 18 years or older and 85 years or younger at the time of consent
Patients with a BMI (Body Mass Index) of 18.0 kg/m2 or higher and 35.0 kg/m2 or lower at screening.
Patients who have provided written consent
AST and ALT levels exceeding three times the upper limit of normal values.
Serum creatinine levels exceeding 1.5 times the upper limit of normal values.
Requirement for continuous oxygen therapy due to pulmonary disease.
Decompensated heart failure at the time of consent.
Patients diagnosed with severe valvular disease by echocardiography.
Deemed unsuitable for this study by the investigator.
Exclusion Criteria for Lab Values Obtained During Cardiac Catheterization
Cardiac Index (CI) obtained by the thermodilution method is 1.8 L/min/m2 or below.
Pulmonary Artery Wedge Pressure (PAWP) is 18 mmHg or higher.
Pulmonary Vascular Resistance (PVR) calculated as (mean PAP - PAWP) / CO is 3.0 Wood or higher, or mean PAP is 25 mmHg or higher.
A sheath could not be placed in the radial artery.
The physician deems the administration of Isosorbide Dinitrate inappropriate due to reasons such as hypotension.
8
| 1st name | Naoto |
| Middle name | |
| Last name | Uemura |
Oita University
Department of Clinical Pharmacology and Therapeutics
8795593
1-1 Idaigaoka, Hasama-Machi, Yufu-Shi, Oita, 879-5593 Japan
0975865952
khayashi@oita-u.ac.jp
| 1st name | Kosuke |
| Middle name | |
| Last name | Hayashi |
Oita University
Department of Clinical Pharmacology and Therapeutics
8795593
1-1 Idaigaoka, Hasama-Machi, Yufu-Shi, Oita, 879-5593 Japan
0975865952
khayashi@oita-u.ac.jp
Oita University
JSPS KAKENHI Grant Number 22K06701
Japanese Governmental office
Nagoya City University Department of Cardiology
Oita University Ethics Committee
1-1 Idaigaoka, Hasama-Machi, Yufu-Shi, Oita, 879-5593 Japan
0975865952
rinrikenkyu@oita-u.ac.jp
NO
| 2024 | Year | 10 | Month | 23 | Day |
Unpublished
Enrolling by invitation
| 2024 | Year | 07 | Month | 12 | Day |
| 2024 | Year | 08 | Month | 28 | Day |
| 2024 | Year | 10 | Month | 28 | Day |
| 2025 | Year | 09 | Month | 30 | Day |
N/A
| 2024 | Year | 10 | Month | 22 | Day |
| 2024 | Year | 12 | Month | 21 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063899